INVIVYD, INC. Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price
INVIVYD, INC. (IVVD) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price of $2.08 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice · last filed 2026-08-13
- INVIVYD, INC. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for the quarter ending 2026-03-31 was $2.20, a 60.92% decline year-over-year.
- INVIVYD, INC. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for the quarter ending 2025-03-31 was $5.63, a 6.94% decline year-over-year.
- INVIVYD, INC. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for the quarter ending 2024-03-31 was $6.05, a 36.25% decline year-over-year.
- INVIVYD, INC. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for the quarter ending 2023-03-31 was $9.49, a 10.39% decline year-over-year.
- INVIVYD, INC. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2025 was $4.01, a 18.50% decline from fiscal 2024.
- INVIVYD, INC. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2024 was $4.92, a 36.27% decline from fiscal 2023.
- INVIVYD, INC. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2023 was $7.72.
- INVIVYD, INC. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2021 was $5.13.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2026-06-30 | $2.08 10-Q · filed 2026-08-13 | |||
| 2026-03-31 | $2.20 10-Q · filed 2026-05-14 | |||
| 2025-12-31 | $4.01 10-K · filed 2026-03-05 | |||
| 2025-09-30 | $4.14 10-Q · filed 2025-11-06 | |||
| 2025-06-30 | $4.21 10-Q · filed 2025-08-14 | |||
| 2025-03-31 | $5.63 10-Q · filed 2025-05-15 | |||
| 2024-12-31 | $4.92 10-K · filed 2025-03-20 | |||
| 2024-09-30 | $4.70 10-Q · filed 2024-11-14 | |||
| 2024-06-30 | $5.56 10-Q · filed 2024-08-14 | |||
| 2024-03-31 | $6.05 10-Q · filed 2024-05-09 | |||
| 2023-12-31 | $7.72 10-K · filed 2024-03-28 | |||
| 2023-09-30 | $7.81 10-Q · filed 2023-11-09 | |||
| 2023-06-30 | $7.78 10-Q · filed 2023-08-10 | |||
| 2023-03-31 | $9.49 10-Q · filed 2023-05-11 | |||
| 2022-12-31 | $10.41 8-K · filed 2024-02-09 | |||
| 2022-09-30 | $10.30 10-Q · filed 2022-11-10 | |||
| 2022-06-30 | $10.62 10-Q · filed 2022-08-15 | |||
| 2022-03-31 | $10.59 10-Q · filed 2022-05-13 | |||
| 2021-12-31 | $5.13 10-K · filed 2022-03-31 | |||
| 2021-09-30 | $2.68 10-Q · filed 2021-11-15 | |||
| 2021-06-30 | $4.61 10-Q · filed 2021-09-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |